Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.22 – $1.43
Volume18,843
Market cap$9M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PLSM.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for PLSM.
Recent news
Company coverage with links to the original publishers.
Several small-cap companies announced significant developments this week: Twin Vee PowerCats is merging with USFM Corporation and pivoting toward critical minerals exploration in Greenland; Xeriant's NEXBOARD construction material passed independent testing; Pulsenmore received $1 million in government-backed AI funding for healthcare applications; and LogProstyle announced a new quarterly dividend.
Pulsenmore Ltd. (NASDAQ: PLSM) reported full year 2025 revenues of $12.5 million, a 374% increase from 2024, though $9.6 million came from a one-time GE settlement. The company reduced net losses to $5 million from $10 million year-over-year and holds $21.7 million in liquid assets. The company achieved FDA clearance for remote prenatal ultrasound in the U.S. and CE certification in Europe, positioning itself for commercial expansion in the prenatal diagnostics market.
Pulsenmore Ltd. (NASDAQ: PLSM) announced its first commercial engagement in the United States with the Center for Fetal Medicine & Women's Ultrasound (CFFM) in Los Angeles. Under the agreement, CFFM will purchase Pulsenmore's home ultrasound services for remote pregnancy monitoring. This milestone follows the company's recent FDA clearance for its home pregnancy ultrasound product and represents a significant step in implementing its U.S. market strategy.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.